YIH
NPCE icon

Y-Intercept (HK)’s Neuropace NPCE Stock Holding History

Y-Intercept (HK)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,894
Closed -$600K – 1886
2025
Q2 		$600K Buy
+53,894
New +$674K 0.01% 1141
2024
Q2 		– Sell
-10,491
Closed -$138K – 1752
2024
Q1 		$138K Buy
+10,491
New +$150K 0.01% 1223

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Y-Intercept (HK)'s NPCE Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 53,894 shares — an estimated $600K sold.

Y-Intercept (HK) first reported a position in NPCE in Q1 2024 and held it in 2 quarters. The position peaked at $600K in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 53,894 Neuropace shares in Q3 2025, an estimated $600K.
  • Y-Intercept (HK) first reported a position in Neuropace in Q1 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Neuropace position peaked at $600K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.